Newron Pharmaceuticals S.p.A. Stock price

Equities

NWRN

IT0004147952

Pharmaceuticals

Delayed Swiss Exchange 10:29:19 2024-03-28 am EDT 5-day change 1st Jan Change
7.74 CHF -1.28% Intraday chart for Newron Pharmaceuticals S.p.A. -1.02% +56.36%

Financials

Sales 2024 * 35.98M 38.88M 35.06M Sales 2025 * 25.95M 28.05M 25.29M Capitalization 149M 161M 145M
Net income 2024 * 13M 14.05M 12.67M Net income 2025 * 4M 4.32M 3.9M EV / Sales 2024 * 4.95 x
Net Debt 2024 * 29.11M 31.46M 28.37M Net Debt 2025 * 2M 2.16M 1.95M EV / Sales 2025 * 5.82 x
P/E ratio 2024 *
10.3 x
P/E ratio 2025 *
34.3 x
Employees 22
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.09%
More Fundamentals * Assessed data
Dynamic Chart
Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Newron Pharmaceuticals S.p.A., 2023 Earnings Call, Mar 19, 2024
Newron Pharmaceuticals' FY23 Loss Narrows; Revenue Up MT
Newron Pharmaceuticals S.p.A. Announces Agreement with the European Investment Bank to Extend the Near-Term Tranche Repayment Dates of Its 2018 Financing Agreement CI
Newron Pharmaceuticals Secures Extension on Three Loan Repayments MT
Newron Pharmaceuticals Investor Subscribes for Nearly EUR6 Million Shares MT
Swiss Equities Edge Higher as Markets Continue to Weigh Rate Cut Outlook MT
Transcript : Newron Pharmaceuticals S.p.A. - Special Call
Newron Reports Exceptional One-Year Results of Study 014/15 with Evenamide in Treatment-Resistant Schizophrenia CI
Newron Pharmaceuticals' Schizophrenia Drug Lowers Disease Severity in Clinical Studies MT
Swiss Equities Rally as Economic Barometer Hits Eight-month High at Year-end MT
Newron Pharmaceuticals Completes Enrolment of Schizophrenia Patients for Evenamide Clinical Study MT
Newron Pharmaceuticals S.p.A. Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A with Evenamide CI
Newron Pharmaceuticals S.P.A. Presents New Data from Study 014/015 Evaluating Its Investigational Drug Evenamide for the Management of Treatment Resistant Schizophrenia CI
Newron Pharmaceuticals S.p.A. Appoints Margarita Chavez as Board Advisor CI
More news

Latest transcript on Newron Pharmaceuticals S.p.A.

1 day-1.28%
1 week-1.02%
Current month-5.61%
1 month-6.75%
3 months+54.18%
6 months+43.33%
Current year+56.36%
More quotes
1 week
7.22
Extreme 7.22
8.10
1 month
7.22
Extreme 7.22
8.60
Current year
4.57
Extreme 4.57
11.45
1 year
3.70
Extreme 3.7
11.45
3 years
1.01
Extreme 1.01
11.45
5 years
0.90
Extreme 0.9
11.45
10 years
0.90
Extreme 0.9
35.85
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 12-05-14
Founder 63 97-12-31
Director of Finance/CFO - 01-12-31
Members of the board TitleAgeSince
Director/Board Member 78 07-12-31
Director/Board Member 74 13-12-31
Founder 63 97-12-31
More insiders
Date Price Change Volume
24-03-28 7.74 -1.28% 65 840
24-03-27 7.84 +4.81% 85,663
24-03-26 7.48 -0.27% 29,328
24-03-25 7.5 +0.81% 66,625
24-03-22 7.44 -4.86% 72,694

Delayed Quote Swiss Exchange, March 28, 2024 at 10:29 am EDT

More quotes
Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
8.003 EUR
Average target price
13.28 EUR
Spread / Average Target
+65.96%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Newron Pharmaceuticals S.p.A. - Swiss Exchange